Author of

• 14490

  +

  P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Biology, Pathology, and Molecular Testing
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 14513

    +

    P2.04-023 - Global Epidemiology of EGFR Mutation in Advanced Non-Small Cell Lung Cancer (ID 1725)

    09:30 - 09:30  |  Author(s): P.R.S. Nunes Filho
    • Abstract

    Background:
    Lung cancer is a leading cause of cancer-related mortality worldwide. Subsets of patients with driver oncogenes can be treated with targeted therapies achieving longer survival than the general population of patients with advanced non-small cell lung cancer. Epidermal growth factor receptor (EGFR) mutations represent an important predictive factor for responses to EGFR inhibitors. This study aims to describe the prevalence of EGFR mutations throughout the world.
    
    Methods:
    We used MEDLINE to searched for articles describing the prevalence of EGFR mutations in countries around the world. Key search terms included “lung cancer”, “NSCLC” and “non-small cell lung cancer” in combination with the following terms: “EGFR”, “EGFR mutation” and “epidermal growth factor receptor”. The search was limited to human studies published in English, Portuguese or Spanish. No date limits were included. All studies describing the prevalence of EGFR mutations were included, provided they used any of the validated testing methods.We excluded the following types of studies: (i) animal xenograft experiments using human cancer cell lines, and (ii) abstracts, letters and posters for which the full study was not published.
    
    Results:
    Our search retrieved 2,369 articles dated from 1989 to 2015, of which 324 were selected based on the criteria described above. 213 of these studies (65.8%) were published between 2011 and 2015; 15 (4.7%) were clinical trials and 306 (98%) were cohort studies, case series or epidemiological series. We found articles from 37 different countries throughout the world, accounting for 121,109 patients. The global prevalence of EGFR mutation was 14.62% (CI 95%; 7.64-21.60%). In an exploratory subgroup analysis by region of the world, gender, smoking status and histology, we found higher prevalence of EGFR mutation in South/East Asia (41.67%; 95%CI: 37.99-45.35%; p<0.001), women (39.68%; 95%CI: 31.49-47-87; p<0.001), non-smokers (54.61%; 95%CI: 45.91-63.31; p<0.001) and adenocarcinoma (35.28%; CI 95%: 28.68-41.90%; p<0.001). Table 1 summarizes the results. Figure 1
    
    
    
    Conclusion:
    To our knowledge this is the most comprehensive study of EGFR mutation prevalence in NSCLC worldwide. Our finds corroborate the estimate that EGFR mutations occur in around 20% of patients and the higher incidence among southeastern populations in Asia, females, non-smokers and adenocarcinoma. Policy makers can use this information to supporting testing of all non-smokers and of patients with adenocarcinoma worldwide.